Dual-modality delivery reduces tumor growth in diffuse midline glioma, highlighting safety and efficacy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Balakrishnan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: